title: [Immediate changes in intraocular pressure after an intravitreal injection of 2.5 mg of bevacizumab].
abstract: OBJECTIVE
  To report the immediate changes of intraocular (IOP) pressure after an intravitreal injection of 2.5mg (0.1 ml) of bevacizumab.
  
  
  METHODS
  Prospective, non-controlled, interventional case series of 45 patients undergoing intravitreal injection of 2.5mg (0.1 mL) of bevacizumab for a variety of retinal disorders. IOP was measured with a Goldmann tonometer at baseline, immediately after, 30 minutes and one day after injection in all of the cases. The main outcome measured was the IOP immediately after injection.
  
  
  RESULTS
  At baseline the mean IOP was 16.6±2.8mm Hg (range, 10-24 mm Hg; median, 16 mm Hg; 25(th) percentile, 14 mm Hg and 75(th) percentile, 18 mm Hg). IOP rose to 53.9±18.2mm Hg (range, 16-78 mm Hg, median, 54 mm Hg; 25(th) percentile, 40 mm Hg and 75(th) percentile, 70 mm Hg; p<0.001) immediately after the injection. After 30 minutes, the IOP normalized but was still higher than baseline with a mean of 19.8±5.2 mm Hg (range, 10-36 mm Hg; median,18 mm Hg; 25(th) percentile,16 mm Hg and 75(th) percentile, 24 mm Hg; P<.01). At 24 hours the IOP was 15.7±3.1 mm Hg (range,10-24 mm Hg; median, 16 mm Hg; 25(th) percentile,14 mm Hg and 75(th) percentile,18 mm Hg; p>0.05).
  
  
  CONCLUSIONS
  An intravitreal injection of 2.5mg (0.1 ml) of bevacizumab causes a transient elevation of IOP that tends to return to normal 30 minutes later.
authors.affiliation: Instituto de Cirugía Ocular, San José, Costa Rica. LW65@cornell.edu
authors.forename: L
authors.initials: L
authors.lastname: Wu
authors.forename: T
authors.initials: T
authors.lastname: Evans
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000139:chemically induced*; D011446:Prospective Studies; D012164:Retinal Diseases / Q000188:drug therapy; D013997:Time Factors; D014065:Tonometry, Ocular
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab